Type
Internal restructuring
Country
Germany
Region
Location of affected unit(s)
Lübeck, Groß Grönau, Selmsdorf
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.20 - Manufacture of pharmaceutical preparations

150 jobs
Number of planned job losses
Job loss
Announcement Date
13 November 2025
Employment effect (start)
13 November 2025
Foreseen end date

Description

The German medical diagnostics company Euroimmun Medizinische Labordiagnostika plans to cut 150 jobs in Germany. The northern sites in Lübeck, Groß Grönau, and Selmsdorf will be affected. The Saxon sites in Bernstadt and Rennersdorf will not be affected.

According to the company, capacities need to be adjusted because demand in the areas of automation and mechanical engineering has declined. According to the company, the positions are to be reduced in a socially responsible manner, primarily through severance packages and transitions into retirement, with only a few layoffs.

Euroimmun is a manufacturer of medical laboratory diagnostics and develops tests, devices, and software for detecting autoimmune, infectious, and allergy-related diseases. It was sold to the U.S. corporation PerkinElmer in 2018 (since 2023 Revvity). Euroimmun operates worldwide and employs 3,400 people in 17 countries.


Sources

Citation

Eurofound (2025), Euroimmun Medizinische Labordiagnostika, Internal restructuring in Germany, factsheet number 203691, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/203691.